Financial PerformanceHarmony is off to a strong start in 2025, reporting 1Q25 net product revenue of $184.7M, up 20% year-over-year, driven by continued commercial execution in narcolepsy.
Product DevelopmentTakeda's Phase 3 success with oveporexton establishes orexin-2 agonism as a validated disease-modifying mechanism in narcolepsy type 1, reinforcing the potential of OX2R agonists to address the underlying cause of NT1.
Revenue GrowthWAKIX continued its upward trajectory, averaging approximately 7,200 patients on therapy and exiting the quarter with approximately 7,300, reinforcing its potential as a $1B+ annual revenue opportunity.